Level B· Emerging clinical evidence with positive signalsClinical TrialPubMed

Timing of intra-articular injection of adipose-derived mesenchymal stem cells affects cartilage integrity and IL-18 expression in spontaneous osteoarthritis: A preclinical study.

Chen MF., Hsu YH., Lin YC., Hu CC., Chiu YT., Ueng SW.

Clinical Trial on Knee Osteoarthritis, Osteoarthritis, Cartilage Damage, published in Int Immunopharmacol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Int Immunopharmacol (2025)
Country
Netherlands
Reported sample size
—
Source database
PubMed
PMID
41448007
DOI
10.1016/j.intimp.2025.115964

Abstract (original English)

Osteoarthritis (OA) is a progressive joint disease primarily characterized by cartilage degradation. A phase I/II clinical trial demonstrated the therapeutic efficacy of a human adipose-derived mesenchymal stem cell (ADMSC) product in patients with knee OA. However, it remains unclear whether its efficacy varies with disease stage or whether a single intra-articular dose offers sustained protection. In this study, we used STR/ort mice-a spontaneous OA model-to evaluate the effects of a single ADMSC injection administered during either early or advancing-stage OA. An additional group received early-stage treatment and was analyzed at a later time point to assess durability. Cartilage integrity, chondrocyte phenotypes, serum cytokines, and subchondral bone structure were examined at three defined time points. Early ADMSC injection significantly reduced matrix-nonproducing chondrocytes, lowered Osteoarthritis Research Society International (OARSI) scores, suppressed aggrecan fragment and matrix metallopeptidase 13 (MMP-13) expression, and increased SRY-box transcription factor 9 (SOX9) levels. In situ RNA hybridization showed that ADMSC xenografts transiently adhered to the cartilage surface and remained detectable post-injection. Micro-computed tomography (micro-CT) demonstrated restored trabecular architecture, while cytokine profiling revealed reduced interleukin-18 (IL-18) lev

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
AnimalsMesenchymal Stem Cell TransplantationInjections, Intra-ArticularHumansMesenchymal Stem CellsMiceInterleukin-18OsteoarthritisCartilage, ArticularChondrocytes

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research